Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380688 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04380688 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 62 participants.
The verdict
NCT04380688, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Interventions
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-06-13 |
| Est. Completion | 2020-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04380688
The ClinicalTrials.gov registry entry for NCT04380688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acalabrutinib is the first listed.
NCT04380688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04380688 about?
NCT04380688 is a clinical study titled "Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.". CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
What is the current status of trial NCT04380688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2020-06-13. Estimated completion is 2020-11-16.
What interventions are being tested in trial NCT04380688?
The interventions under investigation include: Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04380688?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.